For diabetes and related illnesses, recent breakthrough GLP-1’s (Ozempic, Wegovy, Mounjaro…) should be deployed and subsidized as rapidly and broadly as possible.
Deploy and subsidize GLP-1 treatments for diabetes and related illnesses as rapidly and broadly as possible.
Occurrences
CMS will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027.
Evidence
On December 23, 2025, CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model and a separate short-term demonstration (now called the “Medicare GLP-1 Bridge”) that will begin in July 2026 and serve as a bridge to the BALANCE Model in Medicare Part D.
Assessments
There is evidence of real federal action to deploy and subsidize GLP-1 treatments through CMS's Medicare GLP-1 Bridge and BALANCE-related demonstration beginning after Foster's term period in question. However, the record provided does not show that Bill Foster himself authored, sponsored, or materially advanced this outcome. Because the policy movement occurred later and appears driven by executive-agency action rather than Foster's demonstrated contribution, the promise is best scored as only partially fulfilled rather than fully delivered.